Giant cell

NeurologyLive® Announces Giants of Multiple Sclerosis™ Inaugural Class of Inductees

Retrieved on: 
Friday, June 3, 2022
Rehabilitation, MSCS, Headache, Movement disorders, Program, MSN, Epilepsy, Stroke, Gaylord National Resort & Convention Center, Doctor of Philosophy, Food, Multiple, Sclerosis, Degenerative disease, CEO, Migraine, Bristol Myers Squibb, DPT, Convention center, Giant, GLOBE, Patient, Giant cell, MS, Lists of diseases, Multiple sclerosis, Dementia, NCS, Clinical trial, PT, Doctor of Education, Food and Drug Administration, FAAN, CMSC, Pharmaceutical industry

CRANBURY, N.J., June 03, 2022 (GLOBE NEWSWIRE) -- NeurologyLive and the Consortium of Multiple Sclerosis Centers ( CMSC ) today announced the inaugural class of Giants of Multiple Sclerosis inductees.

Key Points: 
  • CRANBURY, N.J., June 03, 2022 (GLOBE NEWSWIRE) -- NeurologyLive and the Consortium of Multiple Sclerosis Centers ( CMSC ) today announced the inaugural class of Giants of Multiple Sclerosis inductees.
  • Giants of Multiple Sclerosis is a premier neuroscience award that celebrates pioneers, innovators and future generations of leaders selected by their peers for their remarkable achievements in multiple sclerosis.
  • Launched in 2021, the Giants of Multiple Sclerosis program recognizes individuals who have reached landmark successes within the field of multiple sclerosis.
  • Out of many nominations, the steering committed selected only nine multiple sclerosis health care professionals to join the prestigious 2022 inaugural class.

Vasculitis Pipeline Insights Report 2022: Comprehensive Insights about 40+ Companies and 40+ Pipeline Drugs - ResearchAndMarkets.com

Retrieved on: 
Thursday, April 21, 2022
Health, Pharmaceutical, Giant, Amputation, NDA, GCA, News, C5a, Giant cell arteritis, Clinical trial, Axial spondyloarthritis, Antidepressant discontinuation syndrome, ANCA, B-cell activating factor, Research, Psoriasis, Giant cell, Novartis, Route of administration, E-selectin, Route, Inflammation, Time-invariant system, III, Psoriatic arthritis, Inactive, AAV, Technology, Discovery, Secukinumab, Blood, ROA, Belimumab, Administration, Acquisition, Vascular disease, Regeneration, Survival, Medical device, Pharmaceutical industry, Vaccine, Vasculitis

The "Vasculitis - Pipeline Insight, 2022" report provides comprehensive insights about 40+ companies and 40+ pipeline drugs in Vasculitis pipeline landscape.

Key Points: 
  • The "Vasculitis - Pipeline Insight, 2022" report provides comprehensive insights about 40+ companies and 40+ pipeline drugs in Vasculitis pipeline landscape.
  • The assessment part of the report embraces, in depth Vasculitis commercial assessment and clinical assessment of the pipeline products under development.
  • Companies and academics are working to assess challenges and seek opportunities that could influence Vasculitis R&D.
  • Vasculitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.

Theramex Announces an Agreement with Enzene Biosciences Limited for the Development and Commercialisation of Tocilizumab, a Biosimilar for the Treatment of Rheumatoid Arthritis

Retrieved on: 
Thursday, December 23, 2021
Biotechnology, Pharmaceutical, Health, Other Health, Giant, Laboratory, Tocilizumab, Alkem Laboratories, CAR, Patient, Pain, Methotrexate, Joint, Fatigue, CMO, Swelling, RA, Giant cell arteritis, Fertility, Birth, Flare, Adult, Disease-modifying antirheumatic drug, Giant cell, Rheumatoid arthritis, Man, Health, Solution, Bone, MTX, CDMO, Osteoporosis, Woman, Nonsteroidal anti-inflammatory drug, CRS, Partnership, Menopause, Fine chemical, Pharmaceutical industry, Theramex, Rheumatology, Theramex, Enzene Biosciences Ltd., THERAMEX, ENZENE BIOSCIENCES LTD.

Tocilizumab, in combination with Methotrexate (MTX), is indicated for the treatment of rheumatoid arthritis.

Key Points: 
  • Tocilizumab, in combination with Methotrexate (MTX), is indicated for the treatment of rheumatoid arthritis.
  • Rheumatoid arthritis is a chronic condition that causes pain, swelling and stiffness in the joints.
  • Some people with rheumatoid arthritis also experience problems in other parts of the body, or more general symptoms such as tiredness and weight loss1.
  • For more information on Enzene Biosciences Ltd., please visit www.enzene.com
    For more information on Alkem Laboratories Ltd., please visit www.alkemlabs.com

Kiniksa Announces American College of Rheumatology Convergence 2020 Late-Breaking Abstracts Presentation of Mavrilimumab Phase 2 Giant Cell Arteritis Data

Retrieved on: 
Monday, November 9, 2020
Medical specialties, Clinical medicine, Medicine, Rheumatology, Giant cell arteritis, Arteritis, Jaw claudication, Claudication, Giant cell, Headache, Arteritic anterior ischemic optic neuropathy, Necrotizing vasculitis

There is a real need for novel therapies for patients with giant cell arteritis, said Dr. Maria Cid,Hospital Clnic,University of Barcelona, IDIBAPS.

Key Points: 
  • There is a real need for novel therapies for patients with giant cell arteritis, said Dr. Maria Cid,Hospital Clnic,University of Barcelona, IDIBAPS.
  • The Phase 2 trial randomized 70 patients 3:2 to mavrilimumab 150 mg (n=42) or placebo (n=28) biweekly injected subcutaneously, co-administered with a protocol-defined 26-week oral corticosteroid taper.
  • Cranial giant cell arteritis typically presents with headache and jaw claudication as well as constitutional symptoms of fever and fatigue.
  • The large vessel form of giant cell arteritis affects the branches of the aorta supplying the trunk and limbs.

Kiniksa Announces New Data from Phase 2 Trial of Mavrilimumab in Giant Cell Arteritis to be Presented at Late-Breaking Abstracts Session of American College of Rheumatology Convergence 2020

Retrieved on: 
Monday, October 26, 2020
Medical specialties, Clinical medicine, Medicine, Rheumatology, Giant cell arteritis, Jaw claudication, Arteritis, Claudication, Giant cell, Headache, Necrotizing vasculitis, Arteritic anterior ischemic optic neuropathy

[5] Two-sided p-value and 95% CI for the difference in sustained remission between two arms using normal approximation.

Key Points: 
  • [5] Two-sided p-value and 95% CI for the difference in sustained remission between two arms using normal approximation.
  • [7] Comparison of KPL-301 and placebo with respect to time to flare calculated by using a log-rank test.
  • Cranial giant cell arteritis typically presents with headache and jaw claudication as well as constitutional symptoms of fever and fatigue.
  • The large vessel form of giant cell arteritis affects the branches of the aorta supplying the trunk and limbs.

Kiniksa Announces Positive Data from Phase 2 Trial of Mavrilimumab in Giant Cell Arteritis

Retrieved on: 
Tuesday, October 6, 2020
Medical specialties, Medicine, Clinical medicine, Rheumatology, Giant cell arteritis, RTT, Jaw claudication, Arteritis, Giant cell, Claudication, GCA, Headache

HAMILTON, Bermuda, Oct. 06, 2020 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (Kiniksa), a biopharmaceutical company with a pipeline of clinical-stage assets designed to modulate immunological pathways across a spectrum of diseases, announced positive data from the global Phase 2 trial of mavrilimumab in giant cell arteritis (GCA).

Key Points: 
  • HAMILTON, Bermuda, Oct. 06, 2020 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (Kiniksa), a biopharmaceutical company with a pipeline of clinical-stage assets designed to modulate immunological pathways across a spectrum of diseases, announced positive data from the global Phase 2 trial of mavrilimumab in giant cell arteritis (GCA).
  • We are thrilled to report that both the primary and secondary efficacy endpoints in the Phase 2 trial of mavrilimumab in giant cell arteritis achieved statistical significance, said Sanj K. Patel, Chief Executive Officer and Chairman of the Board of Kiniksa.
  • These data suggest mavrilimumab may offer a treatment option for patients suffering from giant cell arteritis and further demonstrate the potential broad utility of mavrilimumab.
  • Cranial giant cell arteritis typically presents with headache and jaw claudication as well as constitutional symptoms of fever and fatigue.